Amirali H. Salmasi, MD, presented “Biomarkers for Bladder Cancer” during the 30th Annual Perspectives in Urology: Point-Counterpoint, on March 10, 2023, at Humphreys Half Moon Inn, San Diego, California.

How to cite: Salmasi, Amirali H. Biomarkers for Bladder Cancer.” March 10, 2023. Accessed Jun 2024.

 Biomarkers for Bladder Cancer – Summary

Amirali H. Salmasi, MD, delivers a comprehensive presentation on the significance of biomarkers in detecting and monitoring bladder cancer. He reviews the various types and classifications of biomarkers, and their role in identifying the presence or confirmation of diseases and medical conditions, including bladder cancer.

Dr. Salmasi focuses on the concept of response biomarkers, shedding light on how changes in biomarker levels can indicate the efficacy of exposure or treatment. He delves into the specific mechanisms and capabilities of URO17 and ADXBLADDER tests, both of which exhibit promising sensitivity and specificity in detecting bladder cancer.

Concluding the presentation, Dr. Salmasi emphasizes the need for large-scale validation studies to confirm the role of these biomarkers. He mentions the potential role of circulating free DNA, the emerging significance of microRNA, extracellular vesicles, exosomes, and artificial intelligence in revolutionizing the field of biomarker research.


About the 30th Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.